Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

"Inactive" ingredients in oral medications.

Reker D, Blum SM, Steiger C, Anger KE, Sommer JM, Fanikos J, Traverso G.

Sci Transl Med. 2019 Mar 13;11(483). pii: eaau6753. doi: 10.1126/scitranslmed.aau6753. Review.

PMID:
30867323
2.

Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.

Driessler F, Miguelino MG, Pierce GF, Peters RT, Sommer JM.

Blood Coagul Fibrinolysis. 2017 Oct;28(7):540-550. doi: 10.1097/MBC.0000000000000638.

3.

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.

Toby GG, Liu T, Buyue Y, Zhang X, Bitonti AJ, Pierce GF, Sommer JM, Jiang H, Peters RT.

PLoS One. 2016 Feb 3;11(2):e0148255. doi: 10.1371/journal.pone.0148255. eCollection 2016.

4.

Collateral Report of Psychopathy: Convergent and Divergent Validity of the Psychopathic Personality Inventory-Short Form.

Iyican S, Sommer JM, Kini S, Babcock JC.

J Forens Psychiatry Psychol. 2015 Jul 1;26(4):476-492.

5.

A single chain variant of factor VIII Fc fusion protein retains normal in vivo efficacy but exhibits altered in vitro activity.

Buyue Y, Liu T, Kulman JD, Toby GG, Kamphaus GD, Patarroyo-White S, Lu Q, Reidy TJ, Mei B, Jiang H, Pierce GF, Sommer JM, Peters RT.

PLoS One. 2014 Nov 21;9(11):e113600. doi: 10.1371/journal.pone.0113600. eCollection 2014.

6.

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.

Sommer JM, Buyue Y, Bardan S, Peters RT, Jiang H, Kamphaus GD, Gray E, Pierce GF.

Thromb Haemost. 2014 Nov;112(5):932-40. doi: 10.1160/TH13-11-0971. Epub 2014 Aug 21.

7.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Vigliani G, Brennan A, Luk A, Pierce GF; B-LONG Investigators.

N Engl J Med. 2013 Dec 12;369(24):2313-23. doi: 10.1056/NEJMoa1305074. Epub 2013 Dec 4.

8.

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.

Sommer JM, Moore N, McGuffie-Valentine B, Bardan S, Buyue Y, Kamphaus GD, Konkle BA, Pierce GF.

Haemophilia. 2014 Mar;20(2):294-300. doi: 10.1111/hae.12296. Epub 2013 Nov 22.

9.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Dodd N, Nugent K, Vigliani G, Luk A, Brennan A, Pierce GF; A-LONG Investigators.

Blood. 2014 Jan 16;123(3):317-25. doi: 10.1182/blood-2013-10-529974. Epub 2013 Nov 13.

10.

[Society, the patient, the family physician and....tomorrow].

Bischoff T, Herzig L, Sommer JM, Haller DM.

Rev Med Suisse. 2012 May 16;8(341):1035-6. French. No abstract available.

PMID:
22730637
11.

Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.

Pan J, Liu T, Kim JY, Zhu D, Patel C, Cui ZH, Zhang X, Newgren JO, Reames A, Canivel D, Jesmok G, Pierce GF, Sommer JM, Jiang H.

Blood. 2009 Sep 24;114(13):2802-11. doi: 10.1182/blood-2009-03-212423. Epub 2009 Aug 4.

12.

Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.

Hauck B, Murphy SL, Smith PH, Qu G, Liu X, Zelenaia O, Mingozzi F, Sommer JM, High KA, Wright JF.

Mol Ther. 2009 Jan;17(1):144-52. doi: 10.1038/mt.2008.227. Epub 2008 Oct 21.

13.

Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography.

Qu G, Bahr-Davidson J, Prado J, Tai A, Cataniag F, McDonnell J, Zhou J, Hauck B, Luna J, Sommer JM, Smith P, Zhou S, Colosi P, High KA, Pierce GF, Wright JF.

J Virol Methods. 2007 Mar;140(1-2):183-92. Epub 2006 Dec 28.

PMID:
17196264
14.

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA.

Nat Med. 2006 Mar;12(3):342-7. Epub 2006 Feb 12. Erratum in: Nat Med. 2006 May;12(5):592. Rasko, John [corrected to Rasko, John JE]; Rustagi, Pradip K [added].

PMID:
16474400
15.

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.

Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, Zhou S, Couto LB, Pierce GF.

Blood. 2006 Mar 1;107(5):1810-7. Epub 2005 Oct 25.

16.

AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.

Sanftner LM, Sommer JM, Suzuki BM, Smith PH, Vijay S, Vargas JA, Forsayeth JR, Cunningham J, Bankiewicz KS, Kao H, Bernal J, Pierce GF, Johnson KW.

Exp Neurol. 2005 Aug;194(2):476-83.

17.

Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation.

Wright JF, Le T, Prado J, Bahr-Davidson J, Smith PH, Zhen Z, Sommer JM, Pierce GF, Qu G.

Mol Ther. 2005 Jul;12(1):171-8.

18.

Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events.

Zen Z, Espinoza Y, Bleu T, Sommer JM, Wright JF.

Hum Gene Ther. 2004 Jul;15(7):709-15.

PMID:
15298029
19.

Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.

Wright JF, Qu G, Tang C, Sommer JM.

Curr Opin Drug Discov Devel. 2003 Mar;6(2):174-8. Review.

PMID:
12669452
20.

Quantification of adeno-associated virus particles and empty capsids by optical density measurement.

Sommer JM, Smith PH, Parthasarathy S, Isaacs J, Vijay S, Kieran J, Powell SK, McClelland A, Wright JF.

Mol Ther. 2003 Jan;7(1):122-8.

21.

Trypanosoma brucei: identification of an internal region of phosphoglycerate kinase required for targeting to glycosomal microbodies.

Peterson GC, Sommer JM, Klosterman S, Wang CC, Parsons M.

Exp Parasitol. 1997 Jan;85(1):16-23.

PMID:
9024198
22.

Cloning, expression and characterization of an unusual guanine phosphoribosyltransferase from Giardia lamblia.

Sommer JM, Ma H, Wang CC.

Mol Biochem Parasitol. 1996 Jun;78(1-2):185-93.

PMID:
8813688
23.

Cloning by functional complementation in Trypanosoma brucei.

Sommer JM, Hua S, Li F, Gottesdiener KM, Wang CC.

Mol Biochem Parasitol. 1996 Feb-Mar;76(1-2):83-9.

PMID:
8919997
24.
25.
26.

Targeting proteins to the glycosomes of African trypanosomes.

Sommer JM, Wang CC.

Annu Rev Microbiol. 1994;48:105-38. Review.

PMID:
7826002
27.
28.

A histidine protein kinase homologue required for regulation of bacterial cell division and differentiation.

Ohta N, Lane T, Ninfa EG, Sommer JM, Newton A.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10297-301.

30.

Mouse ornithine decarboxylase is stable in Trypanosoma brucei.

Bass KE, Sommer JM, Cheng QL, Wang CC.

J Biol Chem. 1992 Jun 5;267(16):11034-7.

32.

Evolutionary conservation of a microbody targeting signal that targets proteins to peroxisomes, glyoxysomes, and glycosomes.

Keller GA, Krisans S, Gould SJ, Sommer JM, Wang CC, Schliebs W, Kunau W, Brody S, Subramani S.

J Cell Biol. 1991 Sep;114(5):893-904.

33.

Supplemental Content

Loading ...
Support Center